Illumina’s Clinical Wave: Q2 Beat, Raised Guidance, and the Billion Cell Atlas

Clinical momentum and multi-omics drive a raised outlook as Illumina surfs the NovaSeq X wave.

ILMN · Earnings Call · 2026-07-30

Clinical momentum: a wave, not a cliff

Illumina delivered a standout Q2 2026, with rest-of-world organic revenue growth of 8.1% against a guide of 2–4%, and crucially, management raised the full-year outlook to >5% growth while lifting EPS to $5.30–$5.40. The driver is clinical, which now represents ~65% of sequencing consumables revenue and grew 15% ex-China in the quarter, with the U.S.–Canada region above 20%. “Talking about the clinical cliff, I agree it's not a cliff, it's a wave, we are surfing it” — Jacob Thaysen, Chief Executive Officer (CEO) · 2026-07-30 — Jacob Thaysen captured the tone as placements of NovaSeq X exceeded 95 for a second consecutive quarter, with clinical customers ordering multiple units for new trials. The clinical growth is broad-based and forward-looking: the installed base of X instruments translates into consumable growth over the coming quarters, as recent placements take six to nine months to reach normalized pull-through. “Revenue grew at the fastest rate since I joined the company, driven by increasing demand for Illumina's technology as customers expand clinical applications.” — Jacob Thaysen, Chief Executive Officer (CEO) · 2026-07-30 The company expects mid-teens clinical consumable growth for the year, and the install base is the engine for 2027’s high single-digit algorithm. Notably, the “cliff” worry is mitigated by customers maintaining 6000s in parallel, and management dismissed any near-term headwind from decommissioning.

It’s a wave, we are surfing it, and we think there is a lot of momentum there.
Jacob Thaysen, Chief Executive Officer (CEO) · 2026-07-30

Multi-omics and BioInsight: from sequencing to AI-ready data

Beyond core sequencing, Illumina is making meaningful progress on its 2024 multi-omics strategy. The launch of StrataMap Spatial, a sequencing-based spatial workflow, and the branded SomaScan/SomaSeq offerings are broadening the addressable market. More strategically, the BioInsight initiative is gaining traction: the Cell Atlas has delivered over 300 million cells to date, with six pharma partners (three added after quarter-end) and revenue already booking. “We are making money already from day one on this, both on top line and bottom line.” — Jacob Thaysen, Chief Executive Officer (CEO) · 2026-07-30 This validates the shift from pure instrumentation to high-value data and AI-ready biological models, which Jacob Thaysen called “the foundation for strong AI models.” The company expects new products to add 1–2 points of growth in 2027, reinforcing the raised guidance.

Margin resilience despite cost headwinds

Ankur Dhingra highlighted that Q2 gross margin of 68.2% came in above expectations despite higher freight and memory costs and an unfavorable product mix from strong instrument sales. “I'm really pleased with how the team has continued to operate and find ways that we can compensate for this additional cost.” — Jacob Thaysen, Chief Executive Officer (CEO) · 2026-07-30 The company secured inventory to de-risk memory pricing for several quarters and continues to execute cost actions, with Q3 operating margin guided to ~24% (up 150 bps sequentially). Full-year operating margin is maintained at 23.4–23.6%, and the leverage from consumables mix and cost actions is expected to build into Q4. From a fundamental standpoint, the sequential acceleration is visible in Total Revenue, which at $1.09B in Q1 2026 had been soft but is now guided to ~$4.60–4.64B for the year. Total Revenue TTM is trending toward prior peaks, with Q2 reported revenue of $1.16B, up 9.5% YoY. The stock has responded: +81% in the last 90 days, even though it remains 57% below its 2021 high — a classic re-rating on operational inflection.

Why this matters

Illumina is not just executing on a rebound; it is repositioning from a sequencing hardware company to a multi-omics and AI-driven data business. The raised guidance is conservative, with management explicitly noting potential upside from research recovery and BioInsight. The prior quarters’ cautious tone — “We are only one quarter into the year, so I think it is that we are leaning in by raising both the top line and the bottom line very early in the year” — Jacob Thaysen, Executive (likely CEO or President) · 2026-04-30 — has shifted to visible momentum. As “As Jacob said, we're not seeing any change in the momentum, especially in the clinical business.” — Ankur Dhingra, CFO · 2026-02-05 The confluence of clinical penetration, multi-omics monetization, and margin discipline makes this a rare animal: a large-cap healthcare name with accelerating top-line, expanding margins, and a fresh AI angle. The question is how long the wave lasts — but for now, Illumina is riding it high.